News
-
-
PRESS RELEASE
Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting
Crofelemer shows promising results in reducing total parenteral support for MVID patients, presented at NASPGHAN. Jaguar Health's investigation explores breakthrough benefits for pediatric patients with intestinal failure -
-
PRESS RELEASE
REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrit
Ongoing trial of crofelemer in UAE shows reduction in parenteral support for pediatric intestinal failure patients. Breakthrough in MVID and SBS-IF treatment -
-
PRESS RELEASE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health, Inc. (NASDAQ:JAGX) granted RSUs to new employees effective October 20, 2025. RSUs vest over one year. The Company focuses on developing prescription medicines from rainforest plants for gastrointestinal distress -
-
PRESS RELEASE
Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)
Napo Pharmaceuticals provides update on ongoing clinical trial for the treatment of MVID in pediatric patients, showing significant reduction in parenteral support in UAE. FDA advice sought for study advancement -
-
PRESS RELEASE
FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease
Jaguar Health announces expanded access programs for pediatric patients with microvillus inclusion disease using crofelemer powder. Positive results from initial trials presented
